News | Embolization devices | June 05, 2025

Penumbra Introduces Ruby XL System for Vascular Embolization

Penumbra's Ruby XL System for vascular embolization has received FDA clearance.

 

Penumbra Introduces Ruby XL System for Vascular Embolization

June 5, 2025 – Penumbra, Inc. has announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby XL System, the longest, largest and softest coil on the market[i]. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolization[ii].

"We’ve engineered Ruby XL to deliver more volume per coil than any other coil on the market, which may result in cost savings,” said Shruthi Narayan, President of Interventional Business at Penumbra, Inc. “Ruby XL embodies Penumbra’s commitment to innovation, delivering mechanical occlusion through more volume without sacrificing softness or deliverability.”

The Ruby XL System introduces three unique technologies — Ruby XL, POD® XL, and Packing Coil XL — all of which can be delivered through a 0.035”+ diagnostic catheter. They have a primary diameter of .030" and are designed for procedural efficiency. These coils offer more volume (up to 40mm in size) and are available in extended lengths up to 70 cm.

  • Engineered with a 3D complex shape, Ruby XL coil is designed to frame aneurysms in a variety of clinical applications.
  • POD XL features a hybrid, multistage design and is engineered with three-in-one coil occlusion technology — an anchoring segment, a framing segment, and a dense filling segment. Designed for high flow vessels, POD XL offers smooth delivery and targeted vessel control.
  • Packing Coil XL features an innovative liquid metal wave shape technology, which is designed to adjust dynamically to the size of any vessel (up to 70 cm length).

Penumbra’s Ruby portfolio of peripheral embolization products, now with Ruby XL System, provides physicians with one of the most expansive embolization offerings, enabling physicians to have the latest coil technologies and most extensive options for every case. For more information, please visit www.penumbrainc.com/products/ruby-xl.

 

[i] Data as of May 2025, Ruby XL System is the largest and longest detachable embolization coil commercially available and the only 035 packing coil commercially available.

[ii] Ruby XL is 2X larger than Ruby 020 coils and 3X larger than conventional 035 coils. Fewer coils used may potentially lead to reduced radiation exposure.

 


Related Content

News | FDA

Jan. 13, 2026 – Innovative Health, Inc. has received its 50th clearance from FDA to reprocess single-use medical devices ...

Home January 15, 2026
Home
News | FDA

Jan. 12, 2026 — HeartLung Corp. has announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD, its AI ...

Home January 12, 2026
Home
News | FDA

Jan. 6, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the FDA approval of the Gore Viabahn ...

Home January 06, 2026
Home
News | FDA

Dec. 22, 2025 — Abbott recently announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt ...

Home January 05, 2026
Home
News | FDA

Dec. 18, 2025 — Huxley Medical has announced the SANSA home sleep apnea test has received regulatory clearance from the ...

Home December 19, 2025
Home
News | FDA

Dec. 18, 2025 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer ...

Home December 18, 2025
Home
News | FDA

Dec. 15, 2025 — HeartSciences Inc., a healthcare information technology company advancing the use of ECG/EKGs through ...

Home December 16, 2025
Home
News | FDA

Nov. 25, 2025 — Remington Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance and announced ...

Home December 09, 2025
Home
News | FDA

Dec. 3, 2025 — Atraverse Medical, a medical device company developing next-generation left-heart access technology, has ...

Home December 05, 2025
Home
News | FDA

Dec.1, 2025 – MannKind Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA ...

Home December 01, 2025
Home
Subscribe Now